Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: S&P Capital IQ Quantitative Report
Provider: Stock Traders Daily

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sarepta Therapeutics Inc announces plans to submit new drug application to fda for eteplirsen for treatment of Duchenne Muscular Dystrophy

Monday, 21 Apr 2014 06:55am EDT 

Sarepta Therapeutics Inc:Plans to submit New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) by end of 2014 for approval of eteplirsen for treatment of Duchenne muscular dystrophy (DMD).Eteplirsen is Sarepta's lead exon-skipping drug candidate in development for treatment of patients with DMD who have genotype amenable to skipping of exon 51. 

Company Quote

2 Jul 2015